CDR-Life

Redefining antibody therapies

[CDR-Life @CDRLifeBiotech]

Meet Fabian Scheifele, Head of Discovery at CDR-Life 🧬 For 7+ years, he's led our Discovery team with passion—and moonlighted as our office egg dealer 🥚🚐 Fresh science, fresh eggs, and a love for the outdoors! #TeamTuesday #CDRLife

[CDR-Life @CDRLifeBiotech]

Check out our posters on T-cell engagers for solid tumors at #AACR2025 Chicago:

CDR404 (MAGE‑A4) – more potent with less T-cell exhaustion than a direct competitor (Abs #3494)
CDR505 (KK‑LC‑1) – first‑in‑class, highly specific and potent (Abs #3493) https://t.co/bnqfnA5QsM

[CDR-Life @CDRLifeBiotech]

Say hello to Sophie Barsin, our Portfolio Management expert! Her unique perspective complements our scientists' expertise, creating a balanced approach that drives project success and helps guides promising research toward meaningful outcomes.
Learn more https://t.co/XvH2AwhbX9

[CDR-Life @CDRLifeBiotech]

Pipeline Expansion: CDR111, novel trispecific molecule for immune reset in autoimmune diseases! Plus, oncology updates at #AACR25! Join us on April 28 for TCE data:
· CDR404 – Potential best-in-class MAGE-A4 TCE
· Novel TCE for HLA-A*01/KK-LC-1 tumors
https://t.co/QI7JYpOiQt

[CDR-Life @CDRLifeBiotech]

#InternationalWomensDay! At CDR-Life, we’re inspiring the next generation of scientists. Our team visited Neue Schule Zürich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!

[CDR-Life @CDRLifeBiotech]

Heading to Milan for BIO-Europe Spring! Our Chief Business Officer Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatment—plus what’s ahead for our innovative M-gager® platform. Let’s connect! #BIOEuropeSpring #TCellEngagers

[CDR-Life @CDRLifeBiotech]

Thank you Modern Retina for covering the progress of our collaboration w Boehringer Ingelheim. We’ve reached our 5th milestone as BI 771716, our antibody fragment technology, advances into Ph 2 trials for geographic atrophy. Patient enrollment is underway!
https://t.co/R9dQq4FYAT

[CDR-Life @CDRLifeBiotech]

Proud to have our CBO Sarah Holland chair the Pharma Dealmakers Panel at the #Sachs_ELSF alongside leaders from @Novartis, @Roche, @GSK, @Sanofi & @Secarna discussing the future of biotech partnerships

[CDR-Life @CDRLifeBiotech]

Excited to hold our first Autoimmune Scientific Advisory Board meeting today! With CDR404's clinical progress & our new CDR111 (CD3xCD19xBCMA trispecific) for immune reset, our proprietary antibody-based M-gager® platform expands our unique T cell engager approach to autoimmunity

[CDR-Life @CDRLifeBiotech]

Meet Ivana Tosevski, our Head of Preclinical Safety! Ivana plays a crucial role in ensuring the safety of our molecules before they advance to clinical trials.

Thank you, Ivana, for being an integral member of the CDR-Life family! Learn more about us at https://t.co/XvH2AwhJMH

[CDR-Life @CDRLifeBiotech]

Biotech new year kicks off in SF! 🌉 Heading to #JPM2025 to discuss T cell engagers – an exciting approach for cancer & autoimmune therapies via our unique M-gager® platform. Reach out to chat.

[CDR-Life @CDRLifeBiotech]

Science + People = Magic! David Stocker embodies CDR-Life's spirit. 3 years of great work in therapeutic development. Discover more about our incredible team and science: https://t.co/r9cpxGBjBQ

[CDR-Life @CDRLifeBiotech]

Expanding our leadership team! Sarah Holland joins CDR-Life as Chief Business Officer to drive our M-gager® platform and T cell engager therapies forward. Excited to accelerate our impact in cancer and autoimmune disease treatment. Full details: https://t.co/ftjtz4yFXI

[CDR-Life @CDRLifeBiotech]

Geneva-bound! CDR-Life at #ESMOIO, showcasing M-gager® and CDR404 – our novel T cell engager targeting MAGE-A4 in solid tumors. Let's connect! #ESMOImmuno24

[CDR-Life @CDRLifeBiotech]

Behind game-changing clinical trials is an outstanding leader. Meet Clare Price, VP of Clinical Operations! She's advancing our M-gager platform and T cell engager therapies through expert trial management and unwavering dedication to patient safety. https://t.co/r9cpxGALMi

[CDR-Life @CDRLifeBiotech]

Looking forward to @Jefferies London Healthcare Conference! CEO Christian Leisner and CFO Konstantin von Schulthess will discuss CDR-Life's innovative T cell engager platform targeting hard-to-treat solid cancers and autoimmune diseases. Let's connect! #JefferiesHealthcare

[CDR-Life @CDRLifeBiotech]

Join us at #SITC2024! We're presenting a poster on CDR404, our innovative T cell engager targeting MAGE-A4 in solid tumors such as lung, bladder & head/neck cancers. Stop by our poster or reach out to connect!

[CDR-Life @CDRLifeBiotech]

Meet Stephanie Jungmichel, our Head of Pharmacology! Leading our cell biology research, she drives the development of our T cell engagers (M-gager®) from discovery to clinic. First in our series introducing the brilliant minds behind CDR-Life!

[CDR-Life @CDRLifeBiotech]

Stockholm calling! CDR-Life CEO Christian Leisner is attending #BIOEurope discussing the company’s M-gager portfolio for solid tumors and autoimmune diseases and T cell engager therapeutics pipeline. Drop us a line if you want to connect!

[CDR-Life @CDRLifeBiotech]

It was a pleasure speaking with @Brad Loncar about our T cell engager (TCE) platform to target hard-to-treat tumors. Check out the full interview to learn about our pipeline and upcoming milestones.

[BiotechTV @BiotechTV]

From Zurich: CDR-Life is leveraging its antibody expertise to design highly specific T-cell engagers against targets few others are able to pursue.

Full video: https://t.co/3TLk7xQH57